Post by Moderna on X
Moderna@moderna_tx
XToday we announced that the European Commission has granted marketing authorization for mNEXSPIKE® (mRNA-1283), a new COVID vaccine, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 years and older.
Read more: t.co

314 likes0 repliesPosted Feb 17, 2026